Accent Therapeutics Unveils Promising Data on Innovative KIF18A Inhibitor ATX-295 at AACR 2026
Accent Therapeutics Unveils Promising Data on Innovative KIF18A Inhibitor ATX-295 at AACR 2026
Accent Therapeutics, a pioneering biopharmaceutical company dedicated to advancing precision cancer therapies, recently presented groundbreaking preclinical data on their leading drug candidate, ATX-295, during the American Association for Cancer Research (AACR) Annual Meeting 2026, held in San Diego. This data strongly supports ATX-295 as a potentially best-in-class KIF18A inhibitor, which has demonstrated robust anti-cancer activity across several challenging cancer models characterized by chromosomal instability.
A Game-Changer in Cancer Treatment
The findings presented by Accent Therapeutics illustrate ATX-295's consistent and potent effects on various solid tumors displaying high levels of chromosomal instability. Dr. Serena Silver, Chief Scientific Officer of Accent Therapeutics, emphasized the importance of these results, saying they reinforce the confidence in ATX-295's therapeutic potential. She noted that the molecule targets a critical vulnerability inherent to many aggressive cancers, aligning with the company’s mission to leverage innovative therapies for patient benefit.
Key Findings from Preclinical Research
In the studies reported, ATX-295 exhibited significant anti-tumor activity against several cancer types, including high-grade serous ovarian cancer (HGSOC), squamous non-small cell lung cancer (sqNSCLC), and triple-negative breast cancer (TNBC). The compound's mechanism of action was particularly effective in inducing cell cycle arrest and promoting apoptosis in various cancer cell lines, which are crucial processes for halting tumor growth.
Moreover, ATX-295 led to remarkable tumor regression in patient-derived xenograft models of HGSOC, sqNSCLC, and TNBC that were confirmed to experience whole-genome doubling (WGD) — a common feature in chromosomally unstable tumors. These findings suggest that WGD could serve as a predictive marker for tumor sensitivity to ATX-295, offering promising implications for its therapeutic application in oncology.
Innovative AI Method as a Potential Biomarker
A fascinating aspect of the presentation was the introduction of an AI-based methodology capable of detecting WGD in clinical samples swiftly. This represents a significant advancement in biomarker discovery, enhancing the clinical viability of identifying patients who would most benefit from ATX-295 treatment. The integration of AI tools in assessing chromosomal instability further underscores Accent Therapeutics' commitment to harnessing cutting-edge technology in the fight against cancer.
Clinical Development of ATX-295
ATX-295 is currently undergoing a first-in-human, Phase 1/2 clinical study. This open-label trial is aimed at assessing the safety, tolerability, and initial efficacy of the drug in individuals with locally advanced or metastatic solid tumors, including HGSOC and sqNSCLC. With this development, Accent Therapeutics is making strides towards bringing this innovative treatment to patients who face significant unmet medical needs.
Presentation Details
- - Poster Title: Robust anti-tumor activity of the novel KIF18A inhibitor, ATX-295, in preclinical models of chromosomally instable tumors
- - Abstract Number: 6641
- - Session Title: Multi-Axis Antineoplastic Agents
- - Session Date and Time: April 21, 2026, 2:00 PM – 5:00 PM PT
- - Location: Poster Section 14, Board Number 2
- - Presenter: Dr. Laura Ghisolfi
About Accent Therapeutics
Accent Therapeutics is at the forefront of cancer therapy innovation, focusing on novel small molecule treatments designed to exploit specific vulnerabilities in chromosomally unstable tumors. The company is dedicated to delivering impactful therapeutic options to patients facing severe cancer challenges. Through continued research and clinical trials, Accent is committed to translating extraordinary scientific breakthroughs into lifesaving solutions for those in need. For more information, visit Accent Therapeutics or connect on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.